Back to results
US 2016/0095885 A1Published application
Induction Medium & Methods for Stem Cell Culture & Therapy
AssigneeWibiWorks Therapeutics, Inc.
InventorAline Betancourt
Life of this patent
Estimating the term…
Abstract
Novel MSC stem-cell culture and therapy methods and culture medium compositions for the purpose of inducing, activating, or priming discrete uniform cell phenotypes to selectively promote or suppress inflammation and immunity, yielding primed, activated, or induced cells used in cell-based therapy.
Claims17
An induction medium for inducing a cultured population of MSC stem cells, comprising:
- a Toll-like receptor (TLR) ligand or TLR-ligand inducer;
- erythropoietin (EPO);
- exposure to hypoxia or hypoxia mimetic;
- and
- other known, standard culture-medium components;
- where said TLR ligand induces said MSC stem cells in a predicable manner, yielding expanded and induced, primed, or activated populations of MSC stem cells.
3 more elements
A method for inducing, activating, or priming MSC stein cells, comprising:
- providing a population of MSC stem cells;
- providing an induction medium comprising:
- a Toll-like receptor (TLR) ligand or TLR-ligand inducer;
- erythropoietin (EPO);
- exposure to hypoxia or hypoxia mimetic;
- and
- other known, standard culture-medium components;
- where said TLR ligand induces said MSC stem cells in a predicable manner, yielding expanded and induced, primed, or activated populations of MSC stem cells;
- contacting said MSC stem cells with the induction medium;
- and
- culturing said MSC stem cells under appropriate conditions.
8 more elements
A method of cellular therapy, comprising:
- ex-vivo culturing of expanded and induced, primed, or activated populations of MSC stem cells in an appropriate induction medium comprising:
- a Toll-like receptor (TLR) ligand or TLR-ligand inducer;
- erythropoietin (EPO);
- exposure to hypoxia or hypoxia mimetic;
- and
- other known, standard, variable culture-medium components;
- where said TLR ligand induces said MSC stem cells in a predicable manner, yielding
- expanded and induced, primed, or activated populations of MSC stem cells;
- and
- using the yielded expanded and induced, primed, or activated populations of MSC stem cells as a medicament or therapeutic agent fir cellular therapy.
7 more elements
Dependencies are inferred from the claim text.